



Use of Novel Strategies to Develop Guidelines for Management of Pyogenic Osteomyelitis in Adults

A WikiGuidelines Group Consensus Statement

Brad Spellberg, MD; Gloria Aggrey, MD; Meghan B. Brennan, MD; Brent Footer, PharmD; Graeme Forrest, MD; Fergus Hamilton, MRCP; Emi Minejima, PharmD; Jessica Moore, PharmD, MS, BCPS; Jaimo Ahn, MD, PhD; Michael Angarone, DO; Robert M. Centor, MD; Kartikeya Cherabuddi, MD; Jennifer Curran, PharmD; Kusha Davar, MD; Joshua Davis, MD; Mei Qin Dong, PharmD; Bassam Ghanem, PharmD, MS, BCPS; Doug Hutcheon, MD; Philipp Jent, MD; Minji Kang, MD; Rachael Lee, MD, MSPH; Emily G. McDonald, MD, MSc; Andrew M. Morris, MD, SM; Rebecca Reece, MD; Ilan S. Schwartz, MD, PhD; Miranda So, PharmD, MPH; Steven Tong, MD; Christopher Tucker, MD; Noah Wald-Dickler, MD; Erica J. Weinstein, MD; Riley Williams II, PharmD; Christina Yen, MD; Shiwei Zhou, MD; Todd C. Lee, MD, MPH; for the WikiGuidelines Group

Abstract

IMPORTANCE Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence.

OBJECTIVE To construct a clinical guideline for pyogenic osteomyelitis management, with a new standard of evidence to resolve the gap between strength of recommendation and quality of evidence, through the use of a novel open access approach utilizing social media tools.

EVIDENCE REVIEW This consensus statement and systematic review study used a novel approach from the WikiGuidelines Group, an open access collaborative research project, to construct clinical guidelines for pyogenic osteomyelitis. In June 2021 and February 2022, authors recruited via social media conducted multiple PubMed literature searches, including all years and languages, regarding osteomyelitis management; criteria for article quality and inclusion were specified in the group's charter. The GRADE system for evaluating evidence was not used based on previously published concerns regarding the potential dissociation between strength of recommendation and quality of evidence. Instead, the charter required that clear recommendations be made only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were drafted to discuss pros and cons of care choices. Both clear recommendations and clinical reviews were planned with the intention to be regularly updated as new data become available.

FINDINGS Sixty-three participants with diverse expertise from 8 countries developed the group's charter and its first guideline on pyogenic osteomyelitis. These participants included both nonacademic and academic physicians and pharmacists specializing in general internal medicine or hospital medicine, infectious diseases, orthopedic surgery, pharmacology, and medical microbiology. Of the 7 questions addressed in the guideline, 2 clear recommendations were offered for the use of oral antibiotic therapy and the duration of therapy. In addition, 5 clinical reviews were authored addressing diagnosis, approaches to osteomyelitis underlying a pressure ulcer, timing for the administration of empirical therapy, specific antimicrobial options (including empirical regimens, use of antimicrobials targeting resistant pathogens, the role of bone penetration, and the use of rifampin as adjunctive therapy), and the role of biomarkers and imaging to assess responses to therapy.

CONCLUSIONS AND RELEVANCE The WikiGuidelines approach offers a novel methodology for clinical guideline development that precludes recommendations based on low-quality data or

(continued)

Key Points

Question Can a novel methodology using collaborative research coordinated online be successfully applied to the development of a guideline for the diagnosis and treatment of a common infectious disease, pyogenic osteomyelitis?

Findings This consensus statement and systematic review using a novel WikiGuidelines methodology addresses 7 questions regarding the management of osteomyelitis, resulting in the establishment of 2 clear recommendations (concerning oral antibiotic therapy for pyogenic osteomyelitis and duration of therapy) and 5 clinical reviews that outline a present lack of adequate, hypothesis-confirming data.

Meaning These results suggest that this novel, egalitarian methodology enables a clear separation of established care standards based on hypothesis-confirming evidence from practice preferences that are based on lower quality or no evidence.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

opinion. The primary limitation is the need for more rigorous clinical investigations, enabling additional clear recommendations for clinical questions currently unresolved by high-quality data.

JAMA Network Open. 2022;5(5):e2211321. doi:10.1001/jamanetworkopen.2022.11321

Introduction

An important limitation of traditional clinical guidelines is the frequent dissociation between quality of evidence and strength of recommendations.¹⁻⁶ As a result, some past guideline recommendations have endorsed harmful care, which was only subsequently recognized when high-quality, prospective controlled trials were conducted.⁷ To overcome this limitation, we developed a novel approach, called WikiGuidelines, to establish clear recommendations only when high-quality, hypothesis-confirming evidence is available (see group charter in [Supplement 1](#)).

Our initial social media poll revealed a desire for renewed guidance on a common infectious disease, pyogenic osteomyelitis. Pyogenic osteomyelitis occurs at a rate of approximately 20 cases per 100 000 person-years, with rates rising among patients with diabetes and older patients, as well as those with prosthetic joints.⁸⁻¹⁰ In low- and lower-middle-income countries (LMIC), osteomyelitis may be more common in younger patients as a result of traumatic injury.¹¹ Nevertheless, the global economic burden of osteomyelitis is considerable for high-income countries and LMIC.^{9,10,12-14}

Osteomyelitis is an ancient disease, with the earliest documented case in an unfortunate, 250-million-year-old dimetredon with a fractured spinal shaft.¹⁵ In the modern era, radiography, surgical methods, and antibiotics have revolutionized its management. However, these successful interventions have resulted in long-standing diagnostic and therapeutic paradigms that have guided treatment despite lacking strong evidence, including the need for diagnostic x-rays and intravenous-only antibiotic therapy for all patients.¹⁶ Recent studies have begun to challenge these dogmas.¹⁶⁻¹⁸ This guideline focuses on data regarding management of pyogenic osteomyelitis in adults (see [Supplement 2](#) for the complete guidelines).

Methods

The WikiGuidelines Group formed on Twitter by participants who were dissatisfied with traditional guideline methodologies. The group constructed a charter that specifically chose not to use the GRADE system for evaluating strength of evidence based on previously published concerns regarding bias, poor interrater reliability, and, most importantly, the dissociation between strength of recommendation and quality of evidence ([Supplement 1](#)).¹⁻⁷

Instead, the group sought to incorporate the “humility of uncertainty”⁷ by only providing clear recommendations when reproducible, high-quality, hypothesis-confirming evidence is available, requiring at a minimum: (1) 1 properly conducted, adequately powered randomized controlled trial (RCT); and (2) at least 1 other concordant, prospective, controlled clinical study—either a second RCT, a quasi-experimental pre-post study, a pragmatic nonrandomized trial, or a carefully conducted historically controlled study. In the absence of such data, the charter requires provision of clinical reviews that discuss care choices. However, recognizing the core ethical and clinical principle of “first do no harm,” authors could recommend against the routine provision of unsubstantiated care as part of clinical reviews. We also sought to incorporate principles of high value care (ie, right care, right place, right cost) and health care quality (ie, safe, effective, patient-centered, timely, efficient, equitable).¹⁹

Drafting members participated in reviews for 7 questions regarding the diagnosis and management of pyogenic osteomyelitis. For each question, members conducted their own literature review using PubMed, including all years and languages, with key words that varied by the question

being asked. Articles were assessed for quality and inclusion by criteria specified in the charter. References from identified articles were also searched for potential inclusion. When divergent opinions on article interpretation or clinical practice existed among the authors, we did not attempt to force consensus; rather, in accord with the charter, we sought to transparently highlight those diverging opinions by discussing care alternatives. For answers based on more than 1 relevant RCT, meta-analysis was conducted using Review Manager 5.4.1 (Cochrane Collaboration).

Results

The consortium that established the WikiGuidelines Charter consisted of 63 participants from 8 countries: Australia, Canada, Colombia, Saudi Arabia, Spain, Switzerland, the United Kingdom, and the US. These participants included physicians, pharmacists, and microbiologists with expertise in general internal and hospital medicine, pediatrics, infectious diseases, orthopedic surgery, pharmacology, and medical microbiology.

The participants addressed 7 questions regarding the diagnosis and management of pyogenic osteomyelitis but found data sufficient to establish clear recommendations for only 2: oral antibiotic therapy for pyogenic osteomyelitis and duration of therapy. In contrast, 5 questions were addressed with clinical reviews in the absence of high-quality data: diagnosis of pyogenic osteomyelitis, management of osteomyelitis underlying pressure ulcers, appropriate timing of empirical therapy, rational selection of antimicrobial options, and use of serial biomarkers or imaging studies to evaluate therapeutic response.

Question 1: How Should the Diagnosis of Osteomyelitis Be Established?

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

Osteomyelitis Without Prosthetic Joint Infections (PJI) | Based on observational studies, we do not recommend the routine use of plain x-rays (because of inadequate sensitivity, specificity) or computed tomography scans (inadequate sensitivity) for all patients with a possible diagnosis of osteomyelitis (**Table 1**; eTable 1 in **Supplement 2**) as they may result in unnecessary radiation and use of resources. However, these studies may be helpful if a fracture or other noninfectious cause of bone pain (eg, tumor, foreign object) is prioritized on the differential diagnosis, and/or the pretest probability of osteomyelitis is lower (eg, $\leq 15\%$). Magnetic resonance imaging (MRI) and certain tagged white cell scans are the most accurate imaging modalities for diagnosing osteomyelitis. Inflammatory biomarkers are insufficiently accurate, and we do not recommend their routine use for osteomyelitis diagnosis. Blood cultures have variable sensitivity, but if the patient has systemic symptoms or risk factors for bacteremia (eg, intravenous drug use), isolating likely pathogens (eg, *Staphylococcus aureus*) can be helpful to target with therapy and potentially obviate the need for bone biopsy. If available, bone biopsy for histopathology is highly accurate if positive, but cannot rule out osteomyelitis if negative. Culture of biopsy specimens of the affected bone may help identify etiology and target antimicrobial therapy.

Diabetic Foot Osteomyelitis (DFO) | Based on observational studies, plain x-rays have low sensitivity and specificity for diagnosing DFO (**Table 1**; eTable 1 in **Supplement 2**). The probe-to-bone (PTB) test is simple, noninvasive, and has reasonable sensitivity and specificity as a diagnostic method for DFO, which may preclude the need for imaging in some settings. MRI and certain tagged white cell scans are the most accurate imaging modalities for diagnosing DFO, although their specificities are lower than their sensitivities. Inflammatory biomarkers are insufficiently accurate and we do not recommend their routine use for diagnosis. If available, percutaneous bone biopsy for deep microbiological cultures may help target antimicrobial therapy; surface cultures are not accurate and not recommended.

Osteomyelitis With PJI | There is no established, accurate referent standard diagnostic test for PJI. Certain tagged white cell scans are the most accurate imaging studies for PJI (Table 1; eTable 1 in Supplement 2); however, given the limitations of individual tests, published algorithms are sometimes recommended to establish the diagnosis. Data are limited and inadequate to compare the relative accuracies of competing algorithms. Practically, the diagnosis is typically made from a combination of history, physical examination, imaging studies to assess alternate causes of pain and instability, inflammatory markers, synovial fluid analysis, and/or operative specimens. Molecular

Table 1. Pooled Point Estimates of Sensitivity, Specificity, and Likelihood Ratios for Diagnostic Tests for Osteomyelitis

Test	Sensitivity, %	Specificity, %	Positive LR ^a	Negative LR ^a	Reference
Osteomyelitis without PJI					
X-rays	70	82	3.9	0.4	Llewellyn et al, ⁴⁵ 2019
CT scans	70	90	7.0	0.3	Llewellyn et al, ⁴⁵ 2019
MRI	96	81	5.1	0.05	Llewellyn et al, ⁴⁵ 2019
Nuclear medicine scintigraphy ^b	84	71	2.9	0.2	Llewellyn et al, ⁴⁵ 2019
White cell tagged scans	87	95	17.4	0.1	Llewellyn et al, ⁴⁵ 2019
PET	85	93	12.1	0.2	Llewellyn et al, ⁴⁵ 2019
SPECT	95	82	5.3	0.06	Llewellyn et al, ⁴⁵ 2019
ESR	49-79	50-80	1.6-3.8	0.3-0.4	Ryan et al, ⁴⁶ 2019; Ghassibi et al, ⁴⁷ 2021; Wu et al, ⁴⁸ 2020
CRP	45-76	59-71	1.1-2.6	0.3-0.8	Ryan et al, ⁴⁶ 2019; Ghassibi et al, ⁴⁷ 2021; Wu et al, ⁴⁸ 2020
Biopsy (histopathology)	52	>99	>50	0.5	Pupaibool et al, ⁴⁹ 2015
DFO					
X-rays	62	78	2.8	0.5	Llewellyn et al, ⁵⁰ 2020
MRI	93-96	75-84	3.7-6.0	0.05-0.09	Llewellyn et al, ⁵⁰ 2020; Lauri et al, ⁵¹ 2017
Nuclear medicine scintigraphy ^b	85	68	2.7	0.2	Llewellyn et al, ⁵⁰ 2020
White cell tagged scans	91-92	75-92	3.6-11.5	0.09-0.1	Lauri et al, ⁵¹ 2017
PET	84	93	12.0	0.2	Llewellyn et al, ⁵⁰ 2020
ESR	60-81	56-90	1.4-8	0.2-0.7	Xu et al, ⁵² 2020; Moallemi et al, ⁵³ 2020; Lavery et al, ⁵⁴ 2019; Victoria van Asten et al, ⁵⁵ 2016
CRP	49-76	55-80	1.1-3.8	0.3-0.9	Xu et al, ⁵² 2020; Moallemi et al, ⁵³ 2020; Lavery et al, ⁵⁴ 2019; Markanday, ⁵⁶ 2015
Probe-to-bone	87	83	5.1	0.2	Lam et al, ⁵⁷ 2015
PJI^c					
X-rays	14	70	0.5	1.2	Sconfienza et al, ⁵⁸ 2019
MRI	65-94	73-99	2.4->50	0.06-0.5	Sconfienza et al, ⁵⁸ 2019; Galley et al, ⁵⁹ 2020; Schwaiger et al, ⁶⁰ 2020
Nuclear medicine scintigraphy ^b	83-94	69-90	2.7-9.4	0.07-0.2	Ikeuchi et al, ⁶¹ 2013; Nagoya et al, ⁶² 2008; Ouyang et al, ⁶³ 2014
White cell tagged scans	93-100	91-100	10->50	0.08-<0.01	Erba et al, ⁶⁴ 2014; Teiler et al, ⁶⁵ 2020
PET	82-95	39-87	1.3-7.3	0.06-0.5	Kiran et al, ⁶⁶ 2019; Kwee et al, ⁶⁷ 2008; Jin et al, ⁶⁸ 2014
ESR	75	70-87	2.5-5.8	0.3-0.4	Berberi et al, ⁶⁹ 2010; Pérez-Prieto et al, ⁷⁰ 2017
CRP	88-97	74	3.4-3.7	0.04-0.2	Berberi et al, ⁶⁹ 2010; Pérez-Prieto et al, ⁷⁰ 2017
IL-6	97	91	10.8	0.03	Berberi et al, ⁶⁹ 2010
Synovial WBC count	88	93	12.6	0.1	Qu et al, ⁷¹ 2014
Synovial PMN %	90	88	7.5	0.1	Qu et al, ⁷¹ 2014
Synovial culture	62	94	10.3	0.4	Lee et al, ⁷² 2017

Abbreviations: CRP, C-reactive protein rate; CT, computerized tomography; DFO, diabetic foot osteomyelitis; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; LR, likelihood ratio; MRI, magnetic resonance imaging; PET, positron emission tomography; PJI, prosthetic joint infection; PMN, polymorphonuclear; SPECT, single photon emission computed tomography; WBC, white blood cell.

^a A positive LR ≥5 is helpful and ≥10 is very helpful at shifting posttest probabilities; a negative LR ≤0.2 is helpful and ≤0.1 is very helpful at shifting posttest probabilities.

^b Excluding tagged white cell studies, which are considered separately.

^c Because there is no identified optimal referent standard for the diagnosis of PJI, sensitivity, specificity, and LRs for tests for PJI should be considered to be uncertain estimates.

diagnostic testing is a promising approach, but data are mixed and inadequate to recommend for or against its use as of 2022.

Question 2: What Is the Appropriate Management for Osteomyelitis Underlying a Pressure Ulcer?

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

Observational studies indicate that imaging and inflammatory biomarkers are not diagnostically accurate for osteomyelitis underlying a pressure ulcer and we do not recommend their routine use for this purpose. Antibiotics have not been shown to be of benefit (and may be of harm) in the absence of surgical wound closure, but osteomyelitis may increase the risk of surgical flap failure.^{20,21} Therefore, it may be preferable to avoid the routine use of antibiotic therapy for osteomyelitis underlying a pressure ulcer unless deep bone biopsy confirms osteomyelitis and surgical wound closure is planned, or the patient has accompanying sepsis syndrome or local soft tissue infection. Irrespective of antibiotic use, a multimodal therapeutic approach includes nutritional optimization, wound debridement and care, pressure off-loading, and psychosocial management.

Question 3: When Should Empirical Therapy Be Administered in the Treatment of Osteomyelitis?

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

Some observational studies suggest that administration of antibiotics prior to bone biopsy or surgical management may modestly decrease yield of bone cultures for patients with osteomyelitis, including DFO and PJI. Thus, presuming other microbiological methods (eg, blood cultures) have not already established a microbial etiology, it is reasonable to consider deferring antimicrobial therapy initiation until bone and/or joint microbiological samples are obtained for clinically stable patients. However, other studies are not concordant, and histopathology results are unlikely to be affected by prior short-term antibiotics. Decisions regarding the delay of empirical therapy therefore balance potential harm due to the risk of progression of life-threatening infection (eg, sepsis) or impending spinal cord compression against the potential benefit of microbiological data.

Question 4: Are There Preferred Antibiotics With Which to Treat Osteomyelitis?

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

Which Empirical Antimicrobial Agents Are Preferred for Osteomyelitis? | Based on data from observational studies, if antibiotic therapy cannot be delayed until culture availability, it is reasonable to empirically cover aerobic gram-positive cocci, especially *S aureus*, and gram-negative bacilli (Table 2; eTable 2 in Supplement 2). Many practitioners routinely provide anaerobic coverage for DFO; however, comparative data are not available to establish the clinical benefit or harm of this approach. Inclusion of empirical therapy targeting methicillin-resistant *S aureus* (MRSA) or *Pseudomonas aeruginosa* depends on the presence of specific risk factors (addressed below). In all cases, local susceptibility patterns, patient-specific risk factors, and prior culture data influence the choice of antibiotic selection. Culture results can be used to tailor empirical therapy when possible.

When Should Antimicrobial Coverage Targeting MRSA Be Included? | Based on culture data from observational studies, inclusion of empirical anti-MRSA coverage depends on local prevalence and patient-specific risk factors, such as known colonization status (which is the biggest individual risk factor), prior positive cultures, and health care exposure. In a setting with low MRSA incidence, no known MRSA colonization or prior positive cultures, and minimal health care contact, it is reasonable to withhold empirical MRSA coverage.

When Should Antimicrobial Coverage Against *P Aeruginosa* Be Included? | Based on culture data from observational studies, routine use of empirical antipseudomonal therapy for osteomyelitis is unnecessary. Such agents are added in the presence of specific risk factors, including patients with

Table 2. Reasonable Empirical Antimicrobial Therapy Options With Published Data^a

Types of osteomyelitis	Empirical IV antibiotics ^b	Alternative empirical IV antibiotics	Empirical oral antibiotics ^c
Osteomyelitis without a retained implant	<ul style="list-style-type: none"> Ceftriaxone ± vancomycin 	<ul style="list-style-type: none"> Alternative to β lactam: fluoroquinolone Alternative to vancomycin: linezolid, daptomycin, or clindamycin 	<ul style="list-style-type: none"> TMP-SMX Clindamycin^d Linezolid^d Fluoroquinolone Doxycycline^e ± rifampin
Diabetic foot osteomyelitis	<ul style="list-style-type: none"> Ampicillin-sulbactam Amoxicillin-clavulanate Ceftriaxone^f ± metronidazole ± vancomycin 	<ul style="list-style-type: none"> Alternative to β lactam: fluoroquinolone^f ± metronidazole Alternative to vancomycin: linezolid, daptomycin, or clindamycin 	<ul style="list-style-type: none"> Anoxicillin-clavulanate TMP-SMX Clindamycin^d Linezolid^d Fluoroquinolone or doxycycline^e ± metronidazole ± rifampin
Osteomyelitis with a retained implant (including PJI)			
<3 mos since procedure (early)	<ul style="list-style-type: none"> Antipseudomonal β lactam or ceftriaxone + vancomycin^g 	<ul style="list-style-type: none"> Alternative to β lactam: fluoroquinolone Alternative to vancomycin: linezolid, daptomycin, or clindamycin 	<ul style="list-style-type: none"> Fluoroquinolone ± rifampin If gram-positive confirmed: TMP-SMX or clindamycin^d or linezolid^d or doxycycline^e ± rifampin
≥3 mos after procedure (later onset)	<ul style="list-style-type: none"> Ceftriaxone + vancomycin^g 	<ul style="list-style-type: none"> Alternative to β lactam: fluoroquinolone Alternative to vancomycin: linezolid, daptomycin, or clindamycin 	<ul style="list-style-type: none"> TMP-SMX Clindamycin^d Linezolid^d Fluoroquinolone Doxycycline^e ± rifampin

Abbreviations: PJI, prosthetic joint infection; TMP-SMX, trimethoprim-sulfamethoxazole.

^a This table addresses reasonable therapies with published data to be administered in the absence of available Gram stain, culture, histopathology, or other guiding information that enable targeted therapy. Biopsies should be obtained for such information prior to initiation of therapy when the risk-benefit ratio is favorable. See question 3 in the Results for a thorough discussion of initiation of empirical therapy vs waiting for biopsy information to target therapy. In all cases, antibiotic selection should be adjusted based on local sensitivities for likely target pathogens. This table is not meant to indicate that other therapeutic options cannot be considered for specific patients based on clinical circumstances.

^b Add empirical anti-methicillin-resistant *S aureus* (MRSA) coverage (eg, vancomycin) and/or replace ceftriaxone with an antipseudomonal β lactam (eg, cefepime, piperacillin-tazobactam) if specific risk factors for MRSA (eg, colonization, prior MRSA infection, health care exposure with endemic MRSA) and/or *P aeruginosa* (exposed to prior courses of antibiotics, prior cultures with *P aeruginosa*, gangrenous wounds, recent surgical procedures, specific sites of infection such as malignant otitis externa) are present, respectively (see question 4 in the Results). When such risk factors are present, the authors unanimously preferred the use of noncarbapenem anti-pseudomonal options for stewardship reasons, unless there is a specific concern for extended-spectrum β-lactamase pathogens. Similarly, anti-anaerobic coverage is not routinely needed, but if the wound is gangrenous or there is specific concern for anaerobic infection, metronidazole may be added, or ceftriaxone replaced with ampicillin-sulbactam or amoxicillin-clavulanate. Finally, for patients in whom a MRSA active agent is deemed unnecessary, some authors preferred to add an anti-staphylococcal β-lactam (eg, oxacillin, cloxacillin, nafcillin, ceftazolin) to ceftriaxone.

^c See question 5 in the Results for full discussion of oral therapy, including selection of agents and timing of initiation. Rifampin may be important to add to fluoroquinolones when treating *S aureus* infections, and possibly when treating *Pseudomonas* or *Acinetobacter* infections, to reduce emergence of resistance. Other uses of rifampin are discussed in question 4 of the Results.

^d As clindamycin and linezolid have no reliable gram-negative coverage, they should only be used when the clinician is confident that the infection is not likely caused by a gram-negative pathogen; if there are concerns that gram-negative pathogens may be causing the infection, they should be administered with the addition of a second agent that covers gram-negative pathogens.

^e There are less published data for doxycycline; however, it has been used with anecdotal success and was used in a minority of patients in the OVIVA trial,¹⁰ so it may be an alternative agent in individual patients.

^f Anaerobic coverage is routinely added by many practitioners; however, data are not available to demonstrate whether it adds clinical benefit or not.

^g While many authors would initiate empirical anti-pseudomonal therapy, some authors do not believe that anti-pseudomonal coverage is routinely needed for early PJI infection based on the frequency with which the organism is locally encountered. Most authors who would initiate rifampin preferred to wait until oral transition, but some authors would consider initiating empirical IV rifampin. If rifampin use is being considered, it may be prudent to wait until bacteremia is cleared (if present) and surgical source control is achieved (if necessary), to reduce the risk of treatment failure.^{7,3} See question 4 in the Results for a discussion of empirical pseudomonal therapy and of the potential benefits and/or risks of adjunctive rifampin therapy.

chronic wounds who have: (1) been exposed to multiple prior courses of antibiotics; (2) previously had cultures positive for *P aeruginosa*; (3) gangrenous wounds; (4) had a recent surgical procedure (eg, within 3 months, as with early PJI); or (5) specific sites of infection particularly associated with pseudomonal infection (eg, malignant otitis externa).

Does Bone Penetration of an Antimicrobial Agent Matter Clinically, and Should It Be Used to Select Therapy? | Outcome data related to antibiotic bone penetration are limited for osteomyelitis. Thus, theoretical bone penetration (eTable 3 in Supplement 2) is not the primary driver of antibiotic selection; published clinical outcomes data are more relevant.

Does Adjunctive Rifampin Alter Osteomyelitis Treatment Outcomes; for Which Organisms Is Rifampin Therapy Potentially Useful, and If It Is Used, Is There a Preferred Dosing? | Some observational studies and small RCTs suggest that addition of rifampin to standard therapy may improve long-term outcomes by reducing relapse of osteomyelitis, with or without retained implants or hardware. However, other observational studies and 1 small RCT are contrary. Overall, the data are mixed and remain uncertain (eFigures 1 and 2 in Supplement 2). The use of rifampin in this setting is based on culture results (principally targeting gram-positive cocci or nonfermenting gram-negative bacilli) and individual patient risk-benefit considerations, acknowledging the uncertainty of the efficacy data, side effects, and potential drug interactions (especially those disrupting stable, chronic medications, such as oral anticoagulants or opiates). Studies have not elucidated optimal total daily dosing, except that 450 to 600 mg per dose likely increases pharmacodynamic target attainment and adherence compared with 300 mg multiple daily dosing.²²⁻²⁶


What Is the Role of Long-Acting Glycopeptide Antibiotics in Treating Osteomyelitis? | One RCT and several small, largely single-center, observational studies have examined the role of 2 long-acting glycopeptides, dalbavancin and oritavancin, for the treatment of osteomyelitis.^{27,28} In these studies, the long-acting agents performed similarly to comparator regimens. There are no data supporting their superiority, so the use of these agents is based on risk-benefit considerations, as well as cost and complexity vs other regimens for individual patients and health system contexts.

Question 5: Is Oral Therapy Appropriate for the Treatment of Osteomyelitis, and If So, What Are Reasonable Patient Selection Criteria for Administration?

Clear Recommendation

Based on 8 concordant RCTs comparing intravenous (IV) to oral therapy^{17,29-35} (Figure; eFigure 3 in Supplement 2) and 9 RCTs in which oral therapy was predominantly used in both arms,³⁶⁻⁴⁴ we

Figure. Random-Effects Meta-analysis Forest Plot of Randomized Clinical Trials Comparing Long-term Clinical Success Rates of Oral vs Intravenous (IV) Antibiotic Therapy for Osteomyelitis in Adults



Reproduced with permission from the American Journal of Medicine.¹⁸

recommend oral antibiotic therapy with a drug and/or dose used in published studies as a reasonable option for osteomyelitis of any type (ie, hematogenous, prosthetic, and contiguous, the latter including vertebral and DFO) for patients who: (1) are clinically stable (hemodynamically and at the site of infection, eg, no spinal instability); (2) have adequate source control (ie, not requiring further procedural drainage and without persistent bacteremia); (3) are likely to absorb oral medications from a functioning gastrointestinal tract; (4) have an available regimen used in published osteomyelitis studies to cover likely target pathogens; and (5) have no psychosocial reasons that preclude the safe use of oral therapy. There is no required minimum duration of IV lead-in; patients may be switched to oral therapy when all the above criteria are met, even at the empirical therapy stage. Specific drug options and doses are discussed in the detailed review section (Table 3; eTables 4 and 5 in Supplement 2).

Question 6: What Is the Role and Optimal Utilization of Serial Biomarkers and/or Imaging Studies for Assessing Treatment Response in Osteomyelitis?

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

In the absence of RCTs, observational studies have generally found that neither serial inflammatory biomarkers (eg, erythrocyte sedimentation rate, C-reactive protein) nor routinely repeated imaging accurately predict long-term treatment success for osteomyelitis or PJI for individual patients, nor have they been shown to meaningfully alter treatment decisions beyond clinical observation. Thus, following inflammatory biomarkers and repeated imaging may not offer benefit or contribute to high value care in most patients. Nonetheless, repeated imaging may be useful for patients who are clinically failing therapy to inform source control attempts, identify mechanical complications such as pathological fracture, and/or to trigger reconsideration of the initial diagnosis.

Question 7: What Is the Appropriate Duration of Therapy for Typical Cases of Osteomyelitis?

Clear Recommendation

Osteomyelitis (Including DFO) Without a Retained Implant | Based on 2 RCTs (eFigure 4 in Supplement 2)^{39,44} and concordant observational studies, we recommend a maximum of 6 weeks of antibiotic therapy for hematogenous or contiguous pyogenic osteomyelitis (including DFO), assuming adequate source control (ie, no undrained abscesses too large to be treated with antibiotics alone, possibly ≥2-3 cm in diameter) and no retained prosthetic implant (Table 4;

Table 3. Summary of Oral Antibiotic Doses Used in Published Studies for Osteomyelitis

Drug	Dose	Comments
Ciprofloxacin	500-750 mg twice daily	Higher dose for pseudomonas
Levofloxacin	750 mg once daily	L-enantiomer of ofloxacin, the latter of which was widely studied for osteomyelitis
TMP-SMX	7.5-10 trimethoprim mg/kg/d divided twice or thrice daily (eg, 2 DS tablets twice daily for a 70 kg adult)	Most studies used 7.5-10 mg/kg/d, 2 studies used 4-6 mg/kg/d, with lower cure rates in 1 of them
Clindamycin	600 mg 3 times/d; 900 mg 3 times/d or 600 mg 4 times/d for larger patients	450 mg 4 times/d may be used but was not favored in published studies
Linezolid	600 mg twice daily	Standard dosing, monitor for reversible hematotoxicity after 2 weeks, and irreversible neurotoxicity after 4 wks
Amoxicillin/clavulanate	500 mg 3 times/d or 875 mg twice daily	Specifically for DFO
Rifampin	600 mg once daily	Doses studied include 600 once daily, 900 mg once daily or 600 mg twice daily, unclear if efficacy or toxicity differs; 300 mg doses may be less desirable due to lower AUC levels and less convenience for patients
Fosfomycin ^a	4-16 g per day	Various doses studied with formulations available outside the US, not studied with the sachet powder formulation in the US

Abbreviations: DFO, diabetic foot osteomyelitis; TMP-SMX, trimethoprim-sulfamethoxazole.

^a There are no published data for the treatment of osteomyelitis with the sachet powder oral formulation of fosfomycin available in the US.

eTable 6 in Supplement 2). Insufficient data are available to establish a clear recommendation for durations shorter than 6 weeks (see clinical review below).

Clinical Review (Insufficient Quality of Evidence to Enable a Clear Recommendation)

Osteomyelitis (Including DFO) Without a Retained Implant | Based on small RCTs, 3 or 4 weeks may be a reasonable duration of antibiotics for debrided osteomyelitis, whether hematogenous or contiguous (including DFO); however, confirmatory data are desired. Based on observational studies and 1 small RCT, it is reasonable to refrain from antibiotic use after total resection of infected bone if the treating physicians are confident that all infected bone has been resected. If administered, we do not recommend exceeding 2 to 5 days of therapy if there is no complicating soft tissue infection.

Osteomyelitis With a Retained Implant (Including PJI) | Based on the Duration of Antibiotic Treatment in Prosthetic Osteo-articular infection (DATIPO) RCT,⁴³ participating experts unanimously agree that 12 is preferred to 6 weeks of antibiotics for PJI treated with debridement, antibiotics, and implant retention (DAIR). Some experts also clearly preferred 12 weeks of antibiotics for PJI treated with prosthetic exchanges. However, others believed that equipoise remains between 6 vs 12 weeks for these patients, particularly if *S aureus* is not the etiologic pathogen, or for 1-stage exchanges or 2-stage revisions with negative cultures prior to implantation.

Duration of therapy for other infected implants is not clear. A reasonable strategy, without evidence for or against, may be to treat with antibiotics until the bone heals sufficiently enough that the implants can be removed, such as in cases of fracture. Finally, chronic oral suppressive therapy may be considered for patients for whom the risks and benefits of curative surgery is deemed unacceptable; however, available data have not defined the risks and benefits of this approach well to this point.

Discussion

Based on the results of recent studies, the current approach to pyogenic osteomyelitis and PJI management can increasingly incorporate newer diagnostic and therapeutic concepts. Such changes include recognizing the low value and high cost and burden that plain x-rays incur if routinely ordered for all patients with possible osteomyelitis, reducing or eliminating the routine ordering of low-value, low-accuracy blood biomarkers (eg, inflammatory markers), increasing adoption of oral step-down therapy, and limiting the duration of therapy to the shortest established to be necessary for optimizing cure in RCTs (eg, not more than 6 weeks for osteomyelitis without a prosthetic implant, 12 weeks for PJI treated with DAIR). These changes incorporate considerations of high value care and implementation in LMIC and resource-constrained settings, and thus are applicable across diverse care environments.

Table 4. Summary of Antibiotic Durations for Osteomyelitis

Condition	Clear recommendation	Clinical review
Osteomyelitis without retained implant (including DFO)	Maximum 6 wks	<ul style="list-style-type: none"> • 3-4 wks may be adequate with debridement; confirmatory studies desired
Osteomyelitis with total resection of infected bone	None	<ul style="list-style-type: none"> • No antibiotics is a reasonable option; not recommended for use exceeding 5 d
PJI with DAIR	None	<ul style="list-style-type: none"> • All participating experts preferred 12 wks; a confirmatory, second study is needed to enable a clear recommendation
PJI with exchange	None	<ul style="list-style-type: none"> • 12 wks favored by some experts • Other experts believed equipoise remains for 6 vs 12 wks • 6 wks may be reasonable for non-<i>S aureus</i> pathogens, particularly for 1-stage exchanges • 6 wks may be reasonable for 2-stage exchange, although there is controversy about the need for further antibiotics after the second stage (reimplantation)

Abbreviations: DAIR, debridement, antibiotics, and implant retention; DFO, diabetic foot osteomyelitis; PJI, prosthetic joint infection.

Limitations

The main limitation of this study was that the establishment of only 2 clear recommendations highlights the need for additional high-quality studies of osteomyelitis. In particular, studies are needed regarding new approaches to diagnostics; to elucidate the comparative effectiveness of various antimicrobial options, including adjunctive rifampin or anaerobic therapy; to identify which patients are more likely to relapse after completion of therapy; to further clarify antibiotic durations of therapy; to define the role and optimal methodologies of surgical management; and to define the role of nonantimicrobial adjunctive strategies (eg, hyperbaric oxygen therapy). We also seek to incorporate authors from LMIC countries in future revisions to ensure the WikiGuidelines are broadly applicable to these settings.

Conclusions

WikiGuidelines represent a novel approach to guideline construction, clearly delineating evidenced-based recommendations from opinions based on lower-quality data. Resulting changes in management of pyogenic osteomyelitis include recognizing the low value and high burden that plain x-rays incur if routinely ordered for all patients, reducing the routine ordering of low value, low accuracy blood biomarkers, increasing adoption of oral therapy, and limiting the duration of therapy to the shortest necessary for optimizing cure.

These guidelines are based on published data available as of March 1, 2022. Clinicians who believe other evidence should be considered may contact any of the authors to initiate possible revisions, which the authors intend to complete in close to real-time. The authors understand that no clinical trial can extrapolate to all possible patient care scenarios. Thus, we expect that these guidelines should not establish medicolegal standards of care or replace clinician judgment for individual patients.

ARTICLE INFORMATION

Accepted for Publication: March 19, 2022.

Published: May 10, 2022. doi:10.1001/jamanetworkopen.2022.11321

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2022 Spellberg B et al. *JAMA Network Open*.

Corresponding Author: Brad Spellberg, MD, 2051 Marengo St, Los Angeles, CA 90033 (bspellberg@dhs.lacounty.gov).

Author Affiliations: Los Angeles County+University of Southern California (USC) Medical Center, Los Angeles (Spellberg, Minejima, Davar, Hutcheon, Wald-Dickler); Montgomery Medical Associates PC, Rockville, Maryland (Aggrey); University of Wisconsin Hospital and Clinics, William S. Middleton Memorial Veterans Hospital, Madison (Brennan); Providence Portland Medical Center, Portland, Oregon (Footer); Rush University Medical Center, Chicago, Illinois (Forrest); North Bristol NHS Trust, Bristol, United Kingdom (Hamilton); Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles (Minejima); Providence Little Company of Mary Medical Center, San Pedro, California (Moore); Department of Orthopaedic Surgery, Michigan Medicine, University of Michigan, Ann Arbor (Ahn); Northwestern University Medical Center, Chicago, Illinois (Angarone); Department of Medicine, Birmingham Veterans Affairs (VA) Medical Center, Birmingham, Alabama (Centor); Department of Medicine, University of Florida, Gainesville (Cherabuddi); Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, Ann Arbor (Curran, Zhou); Menzies School of Health Research and Charles Darwin University, Darwin, Australia (Davis); New York Health and Hospitals Bellevue Hospital, New York, New York (Dong); King Abdulaziz Medical City, Jeddah, Saudi Arabia (Ghanem); Department of Infectious Diseases, Inselspital Bern University Hospital, Bern, Switzerland (Jent); University of Texas Southwestern, Dallas (Kang, Yen); Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham (R. Lee); Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Canada (McDonald, T. C. Lee); Department of Medicine, Division of Infectious Diseases, Sinai Health, University Health Network, and University of Toronto, Toronto, Canada (Morris); Section of Infectious Diseases, Department of Medicine, West Virginia University School of Medicine, Morgantown (Reece); Division of

Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (Schwartz); Sinai Health System-University Health Network Antimicrobial Stewardship Program, UHN and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada (So); Victorian Infectious Diseases Service, Royal Melbourne Hospital and University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (Tong); Hospital Medicine, Magnolia Regional Health Center, Corinth, Mississippi (Tucker); Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Weinstein); Pharmacy Service, Oklahoma City VA Health Care System, Oklahoma City, Oklahoma (Williams).

Author Contributions: Dr Spellberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Spellberg, Aggrey, Forrest, Ahn, Angarone, Centor, Cherabuddi, Davar, Dong, Hutcheon, Jent, R. Lee, McDonald, Schwartz, So, Tong, Tucker, Wald-Dickler, Weinstein, Williams, Yen, T. Lee.

Acquisition, analysis, or interpretation of data: Spellberg, Aggrey, Brennan, Footer, Forrest, Hamilton, Minejima, Moore, Ahn, Curran, Davar, Davis, Dong, Ghanem, Jent, Kang, Morris, Reece, Schwartz, So, Tong, Tucker, Weinstein, Williams, Zhou, T. Lee.

Drafting of the manuscript: Spellberg, Aggrey, Brennan, Footer, Forrest, Hamilton, Minejima, Moore, Davar, Davis, Dong, Jent, Kang, R. Lee, Reece, So, Tucker, Wald-Dickler, Weinstein, Yen, T. Lee.

Critical revision of the manuscript for important intellectual content: Spellberg, Aggrey, Brennan, Footer, Forrest, Hamilton, Moore, Ahn, Angarone, Centor, Cherabuddi, Curran, Davar, Davis, Dong, Ghanem, Hutcheon, Jent, Kang, McDonald, Morris, Schwartz, So, Tong, Tucker, Wald-Dickler, Weinstein, Williams, Yen, Zhou, T. Lee.

Statistical analysis: Spellberg, Moore, T. Lee.

Administrative, technical, or material support: Spellberg, Footer, Hamilton, Angarone, Dong, Hutcheon, Kang, R. Lee, Tucker, Yen, T. Lee.

Supervision: Spellberg, Forrest, Ghanem.

Conflict of Interest Disclosures: Dr Forrest reported receiving grants from the Division of Microbiology and Infectious Disease Dalbavancin and from the Veterans Affairs Collaborative Studies Program outside the submitted work. Dr Angarone reported receiving consulting fees from Abbvie DSMB and lecture fees from DKBMed outside the submitted work. Dr So reported a part-time appointment to the Government of Ontario Public Drug Program's Committee to Evaluate Drugs. Dr T. Lee reported receiving salary support from Fonds de Recherche du Quebec-Sante Research and grants from Canadian Institutes of Health Research for clinical trials outside the submitted work. No other disclosures were reported.

Group Information: The WikiGuidelines Group that established this guideline is entirely voluntary and unpaid; the group intends to establish a nonprofit organization to support development of other guidelines using this novel methodology, and eventually intends to trademark the name WikiGuidelines. The WikiGuidelines members appear in [Supplement 3](#).

REFERENCES

1. Packer M. The room where it happens: a skeptic's analysis of the new heart failure guidelines. *J Card Fail*. 2016; 22(9):726-730. doi:10.1016/j.cardfail.2016.07.433
2. Kavanagh BP. The GRADE system for rating clinical guidelines. *PLoS Med*. 2009;6(9):e1000094. doi:10.1371/journal.pmed.1000094
3. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. *JAMA*. 2009;301(8):868-869. doi:10.1001/jama.2009.225
4. Miles KE, Rodriguez R, Gross AE, Kalil AC. Strength of recommendation and quality of evidence for recommendations in current Infectious Diseases Society of America guidelines. *Open Forum Infect Dis*. 2021;8(2):ofab033. doi:10.1093/ofid/ofab033
5. Wright WF, Jorgensen SCJ, Spellberg B. Heaping the pelion of vancomycin on the ossa of MRSA: back to basics in clinical care and guidelines. *Clin Infect Dis*. 2020. doi:10.1093/cid/ciaa1360
6. Brass EP, Hiatt WR. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. *Circulation*. 2017;136(9):785-786. doi:10.1161/CIRCULATIONAHA.117.028888
7. Spellberg B, Wright WF, Shaneyfelt T, Centor RM. The future of medical guidelines: standardizing clinical care with the humility of uncertainty. *Ann Intern Med*. 2021;174(12):1740-1742.
8. Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ III, Huddleston PM III. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. *J Bone Joint Surg Am*. 2015;97(10):837-845. doi:10.2106/JBJS.N.01350

9. Lindbloom BJ, James ER, McGarvey WC. Osteomyelitis of the foot and ankle: diagnosis, epidemiology, and treatment. *Foot Ankle Clin*. 2014;19(3):569-588. doi:10.1016/j.fcl.2014.06.012
10. Zardi EM, Franceschi F. Prosthetic joint infection: a relevant public health issue. *J Infect Public Health*. 2020;13(12):1888-1891. doi:10.1016/j.jiph.2020.09.006
11. Stanley CM, Rutherford GW, Morshed S, Coughlin RR, Beyeza T. Estimating the healthcare burden of osteomyelitis in Uganda. *Trans R Soc Trop Med Hyg*. 2010;104(2):139-142. doi:10.1016/j.trstmh.2009.05.014
12. Geraghty T, LaPorta G. Current health and economic burden of chronic diabetic osteomyelitis. *Expert Rev Pharmacoecon Outcomes Res*. 2019;19(3):279-286. doi:10.1080/14737167.2019.1567337
13. Ferguson J, McNally M, Stubbs D. The financial burden of treating osteomyelitis in the UK. *Orthopaedic Proceedings*. 2019;101-B(suppl_14).
14. Toscano CM, Sugita TH, Rosa MQM, Pedrosa HC, Rosa RDS, Bahia LR. Annual direct medical costs of diabetic foot disease in Brazil: a cost of illness study. *Int J Environ Res Public Health*. 2018;15(1):E89. doi:10.3390/ijerph15010089
15. Moodie RL. Osteomyelitis in the Permian. *Science*. 1921;53(1371):333. doi:10.1126/science.53.1371.333
16. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. *Clin Infect Dis*. 2012;54(3):393-407. doi:10.1093/cid/cir842
17. Li HK, Rombach I, Zambellas R, et al; OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection. *N Engl J Med*. 2019;380(5):425-436. doi:10.1056/NEJMoa1710926
18. Wald-Dickler N, Holtom P, Phillips MC, et al. Oral is the new IV—challenging decades of blood and bone infection dogma: a systematic review. *Am J Med*. 2022;135(3):369-379. doi:10.1016/j.amjmed.2021.10.007
19. American College of Physicians. ACP's High Value Care initiative aims to improve health, avoid harms, and eliminate wasteful practices. American College of Physicians website. Accessed July 18, 2021. <https://www.acponline.org/clinical-information/high-value-care>
20. Wong D, Holtom P, Spellberg B. Osteomyelitis complicating sacral pressure ulcers: whether or not to treat with antibiotic therapy. *Clin Infect Dis*. 2019;68(2):338-342. doi:10.1093/cid/ciy559
21. Crespo A, Stevens NM, Chiu E, Pham V, Leucht P. Incidence of osteomyelitis in sacral decubitus ulcers and recommendations for management. *JBSJ Rev*. 2020;8(6):e0187. doi:10.2106/JBJS.RVW.19.00187
22. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. *Antimicrob Agents Chemother*. 1997;41(12):2670-2679.
23. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. *Rev Infect Dis*. 1983;5(suppl 3):S428-S432.
24. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. *Antimicrob Agents Chemother*. 2003;47(7):2118-2124. doi:10.1128/AAC.47.7.2118-2124.2003
25. Hirai J, Hagihara M, Kato H, et al. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model. *J Infect Chemother*. 2016;22(6):387-394. doi:10.1016/j.jiac.2016.02.011
26. Marsot A, Ménard A, Dupouey J, Allanioux L, Blin O, Guilhaumou R. Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. *Br J Clin Pharmacol*. 2020;86(11):2319-2324. doi:10.1111/bcp.14319
27. Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. *Open Forum Infect Dis*. 2018;6(1):ofy331. doi:10.1093/ofid/ofy331
28. Almgour TA, Alhifany AA. Dalbavancin for the management of osteomyelitis: a major step forward? *J Antimicrob Chemother*. 2020;75(10):2717-2722. doi:10.1093/jac/dkaa188
29. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. *Am J Med*. 1987;82(4A):266-269.
30. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. *Antimicrob Agents Chemother*. 1990;34(1):40-43.
31. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. *J Bone Joint Surg Am*. 1990;72(1):104-110.
32. Gentry LO, Rodríguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. *Antimicrob Agents Chemother*. 1991;35(3):538-541.
33. Gomis M, Barberán J, Sánchez B, Khorrami S, Borja J, García-Barbal J. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. *Rev Esp Quimioter*. 1999;12(3):244-249.

34. Schrenzel J, Harbarth S, Schockmel G, et al; Swiss Staphylococcal Study Group. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. *Clin Infect Dis*. 2004;39(9):1285-1292. doi:10.1086/424506
35. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. *Antimicrob Agents Chemother*. 2009;53(6):2672-2676. doi:10.1128/AAC.01504-08
36. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. *Clin Infect Dis*. 1997;24(4):643-648.
37. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. *Clin Infect Dis*. 2004;38(1):17-24.
38. Lázaro-Martínez JL, Aragón-Sánchez J, García-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. *Diabetes Care*. 2014;37(3):789-795. doi:10.2337/dc13-1526
39. Tone A, Nguyen S, Devery F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. *Diabetes Care*. 2015;38(2):302-307. doi:10.2337/dc14-1514
40. Gariani K, Pham TT, Kressmann B, et al. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, non-inferiority pilot trial. *Clin Infect Dis*. 2020;73(7):e1539-e1545. doi:10.1093/cid/ciaa1758
41. Lora-Tamayo J, Euba G, Cobo J, et al; Prosthetic Joint Infection Group of the Spanish Network for Research in Infectious Diseases—REIPI. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial. *Int J Antimicrob Agents*. 2016;48(3):310-316. doi:10.1016/j.ijantimicag.2016.05.021
42. Benkabouche M, Racloz G, Spechbach H, Lipsky BA, Gaspoz JM, Uçkay I. Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial. *J Antimicrob Chemother*. 2019;74(8):2394-2399. doi:10.1093/jac/dkz202
43. Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. *N Engl J Med*. 2021;384(21):1991-2001. doi:10.1056/NEJMoa2020198
44. Bernard L, Dinh A, Ghout I, et al; Duration of Treatment for Spondylodiscitis (DTS) study group. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. *Lancet*. 2015;385(9971):875-882. doi:10.1016/S0140-6736(14)61233-2
45. Llewellyn A, Jones-Diette J, Kraft J, Holton C, Harden M, Simmonds M. Imaging tests for the detection of osteomyelitis: a systematic review. *Health Technol Assess*. 2019;23(61):1-128. doi:10.3310/hta23610
46. Ryan EC, Ahn J, Wukich DK, Kim PJ, La Fontaine J, Lavery LA. Diagnostic utility of erythrocyte sedimentation rate and C-reactive protein in osteomyelitis of the foot in persons without diabetes. *J Foot Ankle Surg*. 2019;58(3):484-488. doi:10.1053/j.jfas.2018.09.025
47. Ghassibi M, Yen TC, Harris S, Si Z, Leary E, Choma TJ. Responsiveness of routine diagnostic tests for vertebral osteomyelitis may be influenced by the infecting organism. *Spine J*. 2021;21(9):1479-1488. doi:10.1016/j.spinee.2021.04.001
48. Wu Y, Lu X, Hong J, et al. Detection of extremity chronic traumatic osteomyelitis by machine learning based on computed-tomography images: a retrospective study. *Medicine (Baltimore)*. 2020;99(9):e19239. doi:10.1097/MD.00000000000019239
49. Pupaibool J, Vasoo S, Erwin PJ, Murad MH, Berbari EF. The utility of image-guided percutaneous needle aspiration biopsy for the diagnosis of spontaneous vertebral osteomyelitis: a systematic review and meta-analysis. *Spine J*. 2015;15(1):122-131. doi:10.1016/j.spinee.2014.07.003
50. Llewellyn A, Kraft J, Holton C, Harden M, Simmonds M. Imaging for detection of osteomyelitis in people with diabetic foot ulcers: a systematic review and meta-analysis. *Eur J Radiol*. 2020;131:109215. doi:10.1016/j.ejrad.2020.109215
51. Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. *Diabetes Care*. 2017;40(8):1111-1120. doi:10.2337/dc17-0532

52. Xu J, Cheng F, Li Y, Zhang J, Feng S, Wang P. Erythrocyte sedimentation rate combined with the probe-to-bone test for fast and early diagnosis of diabetic foot osteomyelitis. *Int J Low Extrem Wounds*. 2020;20(3):227-231. doi:10.1177/1534734620923278
53. Moallemi SK, Niroomand M, Tadayon N, Forouzanfar MM, Fatemi A. Diagnostic value of erythrocyte sedimentation rate and C reactive protein in detecting diabetic foot osteomyelitis; a cross-sectional study. *Arch Acad Emerg Med*. 2020;8(1):e71.
54. Lavery LA, Ahn J, Ryan EC, et al. What are the optimal cutoff values for ESR and CRP to diagnose osteomyelitis in patients with diabetes-related foot infections? *Clin Orthop Relat Res*. 2019;477(7):1594-1602. doi:10.1097/CORR.0000000000000718
55. Victoria van Asten SA, Gerardus Peters EJ, Xi Y, Lavery LA. The role of biomarkers to diagnose diabetic foot osteomyelitis. a meta-analysis. *Curr Diabetes Rev*. 2016;12(4):396-402. doi:10.2174/1573399811666150713104401
56. Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. *Open Forum Infect Dis*. 2015;2(3):ofv098. doi:10.1093/ofid/ofv098
57. Lam K, van Asten SA, Nguyen T, La Fontaine J, Lavery LA. Diagnostic accuracy of probe to bone to detect osteomyelitis in the diabetic foot: a systematic review. *Clin Infect Dis*. 2016;63(7):944-948. doi:10.1093/cid/ciw445
58. Sconfienza LM, Signore A, Cassar-Pullicino V, et al. Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement). *Eur Radiol*. 2019;29(12):6425-6438. doi:10.1007/s00330-019-06326-1
59. Galley J, Sutter R, Stern C, Filli L, Rahm S, Pfirrmann CWA. Diagnosis of periprosthetic hip joint infection using MRI with metal artifact reduction at 1.5 T. *Radiology*. 2020;296(1):98-108. doi:10.1148/radiol.2020191901
60. Schwaiger BJ, Gassert FT, Suren C, et al. Diagnostic accuracy of MRI with metal artifact reduction for the detection of periprosthetic joint infection and aseptic loosening of total hip arthroplasty. *Eur J Radiol*. 2020;131:109253. doi:10.1016/j.ejrad.2020.109253
61. Ikeuchi M, Okanou Y, Izumi M, et al. Diagnostic value of triple-phase bone scintigraphy for the diagnosis of infection around antibiotic-impregnated cement spacers. *Springerplus*. 2013;2:401. doi:10.1186/2193-1801-2-401
62. Nagoya S, Kaya M, Sasaki M, Tateda K, Yamashita T. Diagnosis of peri-prosthetic infection at the hip using triple-phase bone scintigraphy. *J Bone Joint Surg Br*. 2008;90(2):140-144. doi:10.1302/0301-620X.90B2.19436
63. Ouyang Z, Li H, Liu X, Zhai Z, Li X. Prosthesis infection: diagnosis after total joint arthroplasty with three-phase bone scintigraphy. *Ann Nucl Med*. 2014;28(10):994-1003. doi:10.1007/s12149-014-0899-5
64. Erba PA, Glaudemans AW, Veltman NC, et al. Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study. *Eur J Nucl Med Mol Imaging*. 2014;41(4):615-623. doi:10.1007/s00259-013-2631-4
65. Teiler J, Ahl M, Åkerlund B, et al. Is 99mTc-HMPAO-leukocyte imaging an accurate method in evaluating therapy result in prosthetic joint infection and diagnosing suspected chronic prosthetic joint infection? *Q J Nucl Med Mol Imaging*. 2020;64(1):85-95. doi:10.23736/S1824-4785.19.03040-1
66. Kiran M, Donnelly TD, Armstrong C, Kapoor B, Kumar G, Peter V. Diagnostic utility of fluorodeoxyglucose positron emission tomography in prosthetic joint infection based on MSIS criteria. *Bone Joint J*. 2019;101-B(8):910-914. doi:10.1302/0301-620X.101B8.BJJ-2018-0929.R2
67. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. *Eur J Nucl Med Mol Imaging*. 2008;35(11):2122-2132. doi:10.1007/s00259-008-0887-x
68. Jin H, Yuan L, Li C, Kan Y, Hao R, Yang J. Diagnostic performance of FDG PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis. *Q J Nucl Med Mol Imaging*. 2014;58(1):85-93.
69. Barbari E, Mabry T, Tsaras G, et al. Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and meta-analysis. *J Bone Joint Surg Am*. 2010;92(11):2102-2109. doi:10.2106/JBJS.I.01199
70. Pérez-Prieto D, Portillo ME, Puig-Verdié L, et al. C-reactive protein may misdiagnose prosthetic joint infections, particularly chronic and low-grade infections. *Int Orthop*. 2017;41(7):1315-1319. doi:10.1007/s00264-017-3430-5
71. Qu X, Zhai Z, Liu X, et al. Evaluation of white cell count and differential in synovial fluid for diagnosing infections after total hip or knee arthroplasty. *PLoS One*. 2014;9(1):e84751. doi:10.1371/journal.pone.0084751
72. Lee YS, Koo KH, Kim HJ, et al. Synovial fluid biomarkers for the diagnosis of periprosthetic joint infection: a systematic review and meta-analysis. *J Bone Joint Surg Am*. 2017;99(24):2077-2084. doi:10.2106/JBJS.17.01123

73. Beldman M, Löwik C, Soriano A, et al. If, when, and how to use rifampin in acute staphylococcal periprosthetic joint infections, a multicentre observational study. *Clin Infect Dis*. 2021;73(9):1634-1641. doi:10.1093/cid/ciab426

SUPPLEMENT 1.

WikiGuidelines Charter

SUPPLEMENT 2.

eAppendix. WikiGuidelines Overview, Executive Summary, and Discussion

eFigure 1. Forest Plot of RCTs Comparing Success Rates of Patients Treated With Adjunctive Rifampin or Not for *S. Aureus* Osteomyelitis, With or Without Prosthetic Implants

eFigure 2. Forest Plots of Subsets of RCTs Comparing Rifampin vs No Rifampin for Only Osteomyelitis Without PJI or Only Osteomyelitis With PJI

eFigure 3. Random Effects Meta-analysis Forest Plot of RCTs Comparing Long-term Clinical Success Rates of Oral vs IV Antibiotic Therapy for Osteomyelitis in Adults

eFigure 4. Random Effects Forest Plot of RCTs Comparing Shorter vs Longer Courses of Antibiotic Therapy for Vertebral Osteomyelitis and DFO in Adults

eTable 1. Pooled Point Estimates of Sensitivity, Specificity, and Likelihood Ratios for Diagnostic Tests for Osteomyelitis

eTable 2. Reasonable Empiric Antimicrobial Therapy Options with Published Data

eTable 3. Antibiotic Concentrations in Bone

eTable 4. Treatment Success Rates in Observational Studies of Oral Treatment of Osteomyelitis With or Without Infected Prosthesis in Adults

eTable 5. Summary of Oral Antibiotic Doses Used in Published Studies for Osteomyelitis

eTable 6. Summary of Antibiotic Durations for Osteomyelitis

SUPPLEMENT 3.

Nonauthor Collaborators